BioSpace News Archive

Drug Development

Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure

Phase III data showed the combination of Roche’s Tecentriq and Exelixis’ Cabometyx fell short of its primary endpoint in renal cell carcinoma.

March 3, 2023
·
2 min read
·
Tristan Manalac
Business

FDA Rejected Human Trial for Elon Musk’s BCI Tech - Reuters

In 2022, Elon Musk’s Neuralink tried – and failed – to secure permission from the FDA to run a human trial of its implantable brain-computer interface, according to a report published Thursday.

March 3, 2023
·
2 min read
·
Tristan Manalac
Policy

Sanders Calls on Sanofi, Novo to Follow Lilly in Cutting Insulin Prices

Sen. Bernie Sanders (I-VT), chairman of the Senate’s Health, Education, Labor and Pensions Committee, sent a letter to Sanofi and Novo Nordisk urging them to lower insulin prices.

March 3, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Praxis Shares Fall 48% Following Mixed Data for Essential Tremor Candidate

Shares of Praxis Precision Medicines dropped 48% Friday morning following mixed Phase II results for ulixacaltamide (PRAX-944), its candidate being studied in movement disorder essential tremor.

March 3, 2023
·
1 min read
·
Rosemary Scott
Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar with Endpoints News covering the evolving landscape in vaccine development.

March 3, 2023
·
6 min read
Bio NC

ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference

ProKidney Corp. announced that Dr. Tim Bertram, Chief Executive Officer, will present at TD Cowen’s 43rd Annual Health Care Conference on Tuesday March 7, 2023 at 10:30 AM EST.

March 3, 2023
·
5 min read
Pharm Country

TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab.

March 3, 2023
·
11 min read
Genetown

Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences.

March 3, 2023
·
2 min read
Lone Star Bio

Orthofix Medical to Hold Analyst Teach-In Meeting on March 13, 2023

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will host an Analyst Teach-In Meeting in Lewisville, TX on Monday, March 13, 2023 from 2:30 - approximately 6:30 p.m. CT.

March 3, 2023
·
1 min read
Pharm Country

Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Bristol Myers Squibb Receives European Commission Approval of Reblozyl ® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia.

March 3, 2023
·
12 min read